Moleculin Announces Positive Data for its Pancreatic Cancer Drug Candidate
January 03 2019 - 7:30AM
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the
"Company"), a clinical stage pharmaceutical company focused on the
development of oncology drug candidates, all of which are based on
license agreements with The University of Texas System on behalf of
the M.D. Anderson Cancer Center, today announced that in
preliminary animal studies, a second of its lead drugs, WP1732, has
demonstrated enhanced activity in combination with checkpoint
blockade antibodies in pancreatic cancer.
“After our sponsored research demonstrated that
WP1066 was able to enhance immune checkpoint activity in a
pancreatic cancer animal model,” commented Walter Klemp,
Moleculin’s Chairman and CEO, “we were optimistic that we could
show similar potential results in our water soluble, WP1732 drug
candidate. This is significant for several reasons. It
shows that this is a consistent capability across our platform of
STAT3 inhibitors and it further supports independent research
suggesting that STAT3 may be a key to enabling checkpoint blockade
activity in otherwise resistant tumors. Importantly, though,
when you couple this with our recent findings that WP1732
accumulates disproportionately in the pancreas, we believe it
points to WP1732 as a potentially pivotal new approach to treating
pancreatic cancer. Expansion of the WP1732 and WP1066 in vivo
studies is in progress.”
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage
pharmaceutical company focused on the development of oncology drug
candidates, all of which are based on discoveries made at M.D.
Anderson Cancer Center. The Company’s clinical stage drugs are
Annamycin, an anthracycline designed to avoid multidrug resistance
mechanisms with little to no cardiotoxicity being studied for the
treatment of relapsed or refractory acute myeloid leukemia, more
commonly referred to as AML, and WP1066, an immuno-stimulating
STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML.
Moleculin Biotech is also engaged in preclinical development of
additional drug candidates, including additional STAT3 inhibitors
and compounds targeting the metabolism of tumors.
For more information about the Company, please visit
http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, the ability of
WP1732 to show safety and efficacy in patients. Although Moleculin
Biotech believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Moleculin Biotech has attempted to identify forward-looking
statements by terminology including ''believes,'' ''estimates,''
''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,''
''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under Item 1A. "Risk Factors" in our most recently filed Form 10-K
filed with the Securities and Exchange Commission (“SEC”) and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
ContactsJoe Dorame, Robert Blum or Joe
DiazLytham Partners, LLC602-889-9700mbrx@lythampartners.com
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Apr 2023 to Apr 2024